作者: P. Gisondi , A. Conti , G. Galdo , S. Piaserico , C. De Simone
DOI: 10.1111/BJD.12235
关键词:
摘要: Summary Background Chronic plaque psoriasis is frequently associated with metabolic disorders including obesity. Antitumour necrosis factor α treatments can induce body-weight increase in patients psoriasis. Information on the effect of ustekinumab body weight not available. Objectives To investigate whether therapy changes mass index (BMI) chronic psoriasis. Methods A prospective, multicentre study comparing BMI two closed cohorts during 7-month treatment (n = 79) or infliximab (n = 83). Results Patients treated for 7 months showed a significant (P 2%, compared only 11% those receiving (P = 0·01). In multivariate analysis, all other clinical parameters predicted increase, except use infliximab. At month 7, 96% and 82% achieved at least 50% improvement from their baseline area severity (PASI 50), 69% group 58% PASI 75. There was no difference proportion 50 75 responders between groups. Conclusions contrast to infliximab, does This could be taken into account selection biologics when treating